Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains quality of life in patients with ESR1-mutated, hormone receptor-positive advanced ...

Aromatase inhibitors act through pure oestrogen deprivation to achieve an endocrine response in oestrogen receptor (ER)-positive breast cancer. Both experimental and clinical data now confirm that ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Switching to a new drug combination — camizestrant plus a CDK4/6 inhibitor — sooner may have positive results for advanced breast cancer.

I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want ...

A clinical trial found that women could switch drugs without waiting for scans showing cancer progression, which improved ...

While aromatase inhibitors usually don’t take the place of those treatments, they can offer extra help if you’re in a select group. They’re a hormone therapy used to treat some ovarian ...

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week, suggests that using the Guardant360 CDx test to spot ear | ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and ...